Another busy week – hence a day late with the Weekly Roundup. This week, I cleared one of the flower beds of the dead stems from winter and filled three lawn and leaf bags with leaves and stems. They took … Continue reading ?
The White House has released a detailed blueprint for combating the growing problem of antibiotic resistance, but consumer advocates say the plan lacks specifics for reducing usage in food-producing animals, which contributes significantly to the problem.
In a new report, the World Health Organization is urging European countries to share information about the cost-effectiveness of drugs, and also consider off-label use of medicines, as a way to combat budgetary pressures from rising drug prices.
More states are passing 'right to try' laws to widen access to experimental medicines for people facing life-threatening illnesses, but experts say the laws do not accomplish the goal, while advocates say the laws may spur Congress to act.
The latest comings and goings in the pharmaceutical industry.
And so, yet another working week will soon draw to a close. Not a moment too soon, yes? After all, it has been a rather busy week. Now, though, we get to dream about weekend plans. Once again, the agenda is fairly modest. We expect to catch up on some reading, take a nap or three and possibly check in on the Pharmalot ancestors. Show More Summary
MIT's Bob Langer has another idea: he's looking to change the way that entire courses of treatment are dosed. What if an extended-release formulation, for an oral drug, was really extended release. Days, weeks? Instead of taking pills...Show More Summary
Otsuka Pharmaceuticals flied a lawsuit claming the FDA illegally widened the market for its best-selling Abilify drug, opening the door to generic competition sooner than the drug maker expected.
Engaging patients was a major theme of the eyeforpharma Barcelona 2015 conference (hashtag e4pbarca), which just closed out after 3 days of presentations with a keynote presentation by Dr. Anne Beal, Chief Patient Officer, at Sanofi. "Patients can help in many ways and we (pharma) have to reach out to them all," said Dr. Show More Summary
This is a neat little structure, and it's truly a pain to synthesize (12 steps from myo-inositol). But it now seems to hold the record as the most polar aliphatic compound ever measured, and well it might. David O'Hagan of St. Andrews...Show More Summary
You know, I'm not sure I should have cut Atomwise so much slack the other day. I just came across this piece on them, and...well, I'll let it speak for itself: “Here I am just sitting in this house and I’m able to predict a cure to measles,”...Show More Summary
Hello, everyone, and how are you today? We are feeling bright and shiny this morning, despite the tufts of gloomy fog encircling the Pharmalot campus. After all, every brand new should be unwrapped like a precious gift, as the Morning Mayor used to say. Show More Summary
Hospitals eagerly blame pharmaceutical manufacturers for high specialty drug prices. Yet the new Magellan Rx Management 2014 Medical Pharmacy Trend Report demonstrates how hospitals contribute to drug prices, unashamedly capturing much larger mark ups than do other sites of care. Show More Summary